Practical implication
MAHs should verify their product's status on the additional monitoring list and ensure compliance with labeling requirements for any additions or removals during their next regulatory submission.
Medicines added to the additional monitoring list must display an inverted black triangle and a standard explanatory statement in their documentation. Marketing Authorization Holders (MAHs) need to ensure these updates are implemented during their next regulatory submission. Conversely, products removed from the list are required to remove the triangle from their labeling.
What changed: The EMA's latest update to the additional monitoring list specifies that newly added medicines must now include an inverted black triangle and standard explanatory statement in their package leaflet and Summary of Product Characteristics (SmPC). MAHs must check for additions or removals and adjust labeling according to these changes.
Why it matters: This regulatory action directly impacts the labeling requirements and increases the monitoring intensity for signal management for certain medicines in the EU, thus enhancing patient safety.
Practical implication: MAHs should verify their product's status on the additional monitoring list and ensure compliance with labeling requirements for any additions or removals during their next regulatory submission.
View original source
Published from the Firecrawl policy change extraction pipeline.
